TY - JOUR
T1 - Morphine tolerance and reward but not expression of morphine dependence are inhibited by the selectiveglutamate carboxypeptidase II (GCP II, NAALADase) inhibitor, 2-PMPA
AU - Popik, Piotr
AU - Kozela, Ewa
AU - Wróbel, Malgorzata
AU - Wozniak, Krystyna M.
AU - Slusher, Barbara S.
N1 - Funding Information:
This study was supported by Guilford Pharmaceuticals and by KBN grant 4 P05A 42 17. The authors are grateful to Dr W Danysz, MERZ and Co, Frankfurt/M, Germany for the gift of memantine.
PY - 2003/3
Y1 - 2003/3
N2 - Inhibition of glutamate carboxypeptidase II (GCP II; NAALADase) produces a variety of effects on glutamatergic neurotransmission. The aim of this study was to investigate effects of GCP II inhibition with the selective inhibitor, 2-PMPA, on: (a) development of tolerance to the antinociceptive effects, (b) withdrawal, and (c) conditioned reward produced by morphine in C57/Blmice. The degree of tolerance was assessed using the tail-flick test before and after 6 days of twice daily (b.i.d.) administration of 2-PMPA and 10 mg/kg of morphine. Opioid withdrawalwas measured 3 days after twice daily morphine (30 or 10 mg/kg) administration, followed by naloxone challenge. Conditioned morphine reward was investigated using conditioned place preference with a single morphine dose (10 mg/kg). High doses of 2-PMPA inhibited the development of morphine tolerance (resembling the effect of 7.5 mg/kg of the NMDA receptor antagonist, memantine) while not affecting the severity of withdrawal. A high dose of 2-PMPA (100 mg/kg) also significantly potentiated morphine withdrawal, but inhibited both acquisition and expression of morphine-induced conditioned place preference. Memantine inhibited the intensity of morphine withdrawalaswellas acquisition and expression of morphine-induced conditioned place preference. In addition, 2-PMPA did not affect learning or memory retrievalin a simple two-trialtest, nor did it produce withdrawalsymptoms in morphine-dependent, placebo-challenged mice. Results suggest involvement of GCP II (NAALADase) in phenomena related to opioid addiction.
AB - Inhibition of glutamate carboxypeptidase II (GCP II; NAALADase) produces a variety of effects on glutamatergic neurotransmission. The aim of this study was to investigate effects of GCP II inhibition with the selective inhibitor, 2-PMPA, on: (a) development of tolerance to the antinociceptive effects, (b) withdrawal, and (c) conditioned reward produced by morphine in C57/Blmice. The degree of tolerance was assessed using the tail-flick test before and after 6 days of twice daily (b.i.d.) administration of 2-PMPA and 10 mg/kg of morphine. Opioid withdrawalwas measured 3 days after twice daily morphine (30 or 10 mg/kg) administration, followed by naloxone challenge. Conditioned morphine reward was investigated using conditioned place preference with a single morphine dose (10 mg/kg). High doses of 2-PMPA inhibited the development of morphine tolerance (resembling the effect of 7.5 mg/kg of the NMDA receptor antagonist, memantine) while not affecting the severity of withdrawal. A high dose of 2-PMPA (100 mg/kg) also significantly potentiated morphine withdrawal, but inhibited both acquisition and expression of morphine-induced conditioned place preference. Memantine inhibited the intensity of morphine withdrawalaswellas acquisition and expression of morphine-induced conditioned place preference. In addition, 2-PMPA did not affect learning or memory retrievalin a simple two-trialtest, nor did it produce withdrawalsymptoms in morphine-dependent, placebo-challenged mice. Results suggest involvement of GCP II (NAALADase) in phenomena related to opioid addiction.
KW - Antinociception
KW - Drug reward
KW - Glutamate carboxypeptidase II
KW - Memory
KW - NMDA receptor antagonist
KW - Opioid withdrawaland dependence
KW - Tolerance
UR - http://www.scopus.com/inward/record.url?scp=0037648349&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037648349&partnerID=8YFLogxK
U2 - 10.1038/sj.npp.1300048
DO - 10.1038/sj.npp.1300048
M3 - Article
C2 - 12629525
AN - SCOPUS:0037648349
SN - 0893-133X
VL - 28
SP - 457
EP - 467
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 3
ER -